Kurs
+6,50%
Likviditet
1,57 MSEK
Kalender
| Est. tid* | ||
| 2025-03-28 | N/A | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2025-03-27 | N/A | Årsstämma |
| 2025-02-27 | - | Bokslutskommuniké 2024 |
| 2024-08-16 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-02 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2024-03-28 | - | Årsstämma |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-08-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2023-03-31 | - | Årsstämma |
| 2023-02-27 | - | Bokslutskommuniké 2022 |
| 2022-08-12 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-09 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2022-03-31 | - | Årsstämma |
| 2022-02-28 | - | Bokslutskommuniké 2021 |
| 2021-08-13 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-17 | - | Split NXTMS 100:1 |
| 2021-04-30 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2021-04-29 | - | Årsstämma |
| 2021-03-01 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-08-14 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-01 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-11 | - | Extra Bolagsstämma 2019 |
| 2019-08-16 | - | Kvartalsrapport 2019-Q2 |
| 2019-03-28 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2019-03-26 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2019-03-25 | - | Årsstämma |
| 2019-03-04 | - | Bokslutskommuniké 2018 |
| 2018-11-26 | - | Split NXTMS 30:1 |
| 2018-11-21 | - | Extra Bolagsstämma 2018 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-03-29 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2018-03-28 | - | Årsstämma |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q2 |
| 2017-03-29 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2017-03-28 | - | Årsstämma |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2017-02-17 | - | Extra Bolagsstämma 2017 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-01 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2016-03-31 | - | Årsstämma |
| 2016-02-29 | - | Bokslutskommuniké 2015 |
| 2015-12-22 | - | Extra Bolagsstämma 2015 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-01 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2015-03-31 | - | Årsstämma |
| 2015-02-26 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Press release, Helsinki, 17 February 2025 at 10 AM (EET)
Distributor Orders Nexstim NBS System 5 for European Hospital
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a distributor for a hospital in Europe.
The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for pre-operative mapping of the motor and speech cortices of the brain. The information gained from the mapping may be used in pre-procedural planning. The specific system ordered can also be used for therapy, where the NBS System 5 is CE-marked for the treatment of major depression and chronic neuropathic pain.
Mikko Karvinen, CEO of Nexstim, comments: “We are happy that this neurosurgery end customer chose to acquire another Nexstim system. Our NBS System 5 offers extensive opportunities for use across departments, and we are proud to offer solutions that improve the lives of patients in many areas.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com